Denmark slashes 2025 growth forecast amid Novo Nordisk slowdown

Denmark has significantly downgraded its 2025 GDP growth forecast to 1.4% from 3%, largely attributing the revision to weaker expectations for pharmaceutical giant Novo Nordisk. This stems from a substantial decline in U.S. exports of its weight loss drugs due to inventory build-up, heightened competition, and generic market pressures, compounded by U.S. tariffs and softer Q1 2025 growth. Despite the cut, the economy ministry emphasizes continued overall strength, citing high employment and inflation below 2%, while notably upgrading the 2026 growth outlook to 2.1%.

Analysis

Denmark has significantly revised its 2025 GDP growth forecast downward to 1.4% from a previous estimate of 3.0%, a move largely attributed to a weakened outlook for its dominant pharmaceutical industry, specifically Novo Nordisk (NVO). This revision follows a period of strong expansion, including 3.7% growth last year, which was heavily reliant on pharmaceutical exports. The downgrade is underpinned by a significant decline in U.S. exports in early 2025, which the economy ministry links to a combination of post-spike inventory build-up, intensifying competition in the lucrative weight-loss drug market leading to market share loss for Novo, and encroachment from generic medicines. Compounding these industry-specific issues, U.S. tariffs on European pharmaceuticals have also weighed on the forecast. Despite the sharp 2025 adjustment and weaker-than-expected Q1 growth, the government maintains that the underlying economy remains robust, citing high employment and an inflation forecast below 2%. In a notable contrast, the growth forecast for 2026 has been revised upward to 2.1% from 1.4%, based on expectations of strengthening private and public consumption.

Key Decisions for Investors

• Investors in Novo Nordisk (NVO) should exercise caution and closely monitor for evidence of stabilizing U.S. sales and market share, as the article explicitly cites inventory issues, rising competition, and generic pressure as key headwinds.
• The downgrade highlights the Danish economy's high sensitivity to the performance of its pharmaceutical sector, suggesting that macro investors should treat Novo Nordisk's competitive standing and U.S. export data as primary leading indicators for near-term Danish economic performance.
• Despite the negative 2025 revision, the upgraded 2026 growth forecast to 2.1% and strong domestic fundamentals like high employment and low inflation could signal a potential divergence between Denmark's export-oriented and domestic-focused equities.